Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.
For the treatment of pneumonia due to Pneumocystis carinii.
Fisons Corp, Rochester, New York, United States
Chicago Children's CRS, Chicago, Illinois, United States
Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
Case CRS, Cleveland, Ohio, United States
SUNY - Stony Brook, Stony Brook, New York, United States
SUNY - Stony Brook, Stony Brook, New York, United States
Tulane Univ School of Medicine, New Orleans, Louisiana, United States
Charity Hosp / Tulane Univ Med School, New Orleans, Louisiana, United States
SUNY / State Univ of New York, Syracuse, New York, United States
Justus-Leibig University, Giessen, Germany
University of Alberta, Edmonton, Alberta, Canada
University of Geneva, Geneva, Switzerland
LyphoMed Inc, Rosemont, Illinois, United States
Fisons Corp, Rochester, New York, United States
Community Consortium of San Francisco, San Francisco, California, United States
Denver CPCRA / Denver Public Hlth, Denver, Colorado, United States
Wilmington Hosp / Med Ctr of Delaware, Wilmington, Delaware, United States
Julio Arroyo, West Columbia, South Carolina, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.